코스닥 이야기
Quickly browse recent reports in the selected category.
-
![[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2676d12d4578.84092915.png)
[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September
HLB faces major commercialization milestones with upcoming FDA decisions: the PDUFA target date for its liver cancer therapy on July 23, 2026, and a decision on its cholangiocarcinoma treatment expected by September 27.
-
Alteogen (196170) Enters Era of Scale Milestone Revenues, First Year of Earnings Leap Proven by Royalty Inflows
Alteogen (196170) is set to enter a massive milestone inflow phase driven by its SC platform technology, with billions in cash expected from Keytruda SC sales and new licensing deals amid resolved patent risks.
-
KOSDAQ Flirts with 1,002 Level Amidst KOSPI's Rally past 8,000: Examining Bio/Healthcare ETF Inflows and Second-Half Recovery Scenarios
KOSDAQ faces decoupling at the 1,002.44 level as KOSPI rallies past 8,000. However, persistent K-bio technology exports are driving steady inflows into KOSDAQ active healthcare ETFs, pointing to a potential H2 rebound.
-
KOSDAQ Anchors at 1,002 Level; Examining Classys' (214150) 15% US Revenue Target and Global Expansion Strategy
Global medical aesthetics leader Classys (214150) is accelerating its expansion in the US, the world's largest aesthetic medical market, presenting a long-term roadmap with a 15% revenue share target for North America.
-
KOSDAQ at 1,049: Exploring Clinical Trial Calendars Driven by ADA & Clinical Momentum alongside Valuations of Top 3 Leaders (Alteogen, ABL Bio, Peptron)
KOSDAQ looks to regain momentum with upcoming major conferences like ADA 2026. This article analyzes the technology, clinical calendars, and valuations of top biotech platforms Alteogen, ABL Bio, and Peptron.
-
KOSDAQ Closes at 1,026: Lithium Price Recovery Sparks Turnaround for Battery Material Stocks & Valuation Check for the Top 3 Cathode Makers
Daily Stock analyzes how the recent rebound in global lithium prices is driving a turnaround for KOSDAQ battery material stocks, featuring earnings surprises and key valuation metrics for L&F, EcoPro BM, and POSCO Future M.